NCT06201624View on ClinicalTrials.gov

Oral Isotretinoin in Melasma a Randomized Controlled Trial

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

January 31, 2024

Study Completion Date

May 31, 2024

Conditions
Melasma
Interventions
DRUG

Isotretinoin

Patients will receive 1mg/kg/day for 3 months

DRUG

Triple combination formula

Patients are instructed to apply the triple combination formula at night daily for 3 months

Trial Locations (1)

44511

RECRUITING

Dermatology department, Zagazig University Hospitals, Faculty of Medicine, Zagazig University, Zagazig

All Listed Sponsors
lead

Zagazig University

OTHER_GOV